Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Vet. Sci., 16 January 2026

Sec. Animal Reproduction - Theriogenology

Volume 12 - 2025 | https://doi.org/10.3389/fvets.2025.1699857

This article is part of the Research TopicEndometrial Health and Disease: From Molecular Insights to Clinical AdvancesView all 4 articles

In vitro characterization of antimicrobial efficacy and cytotoxicity of polyvinylpyrrolidone-iodine, N-acetylcysteine, methylglyoxal, and N-chlorotaurine as alternative antimicrobials in treating bovine clinical endometritis

  • Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany

Bovine clinical endometritis (CE) is a common indication for antibiotic use in dairy cows. The increase in bacterial resistance and the aspired decrease in antibiotic use under the One Health concept call for alternatives in treatment. Polyvinylpyrrolidone-iodine (PVP), N-acetylcysteine (NAC), methylglyoxal (MGO), and N-chlorotaurine (NCT) are known substances with antibacterial properties that could potentially serve as those alternatives. In a broth microdilution assay, their efficacy against the common cause of endometritis, Trueperella pyogenes, was investigated. By cytotoxicity testing on a primary bovine endometrial epithelial cell culture, potential adverse effects on cell proliferation, viability, and immune response (IL-6) were examined. While all four substances had an antibacterial effect on T. pyogenes, PVP, MGO, and NCT also showed cytotoxic effects. In contrast, NAC was tolerated well by the cells. In sum, the four tested substances can be considered potential alternatives to antibiotic treatments. Further research is, however, necessary to investigate their toxic effects in ex vivo or in vivo models and to identify effective dosages in animals.

1 Introduction

Bovine clinical endometritis (CE) is defined by Sheldon et al. (1) as an illness showcasing mucopurulent or purulent uterine discharge 21 days postpartum or later. It is not accompanied by any systemic clinical symptoms. In addition to uterine discharge, endometrial inflammation is a key component of CE (2). Cows with CE suffer not only from the illness itself, which lowers animal welfare, but also from higher rates of infertility or subfertility, which lead to economic losses for the farmer and increased culling of affected animals (3). The pathogenesis of CE involves three major pathogenic pathways: alterations in immune function (4, 5), metabolic stress (6, 7), and shifts in the uterine microbiome (8, 9). For the latter, various pathogens have been identified as playing a role in CE. One of the most common bacteria is Trueperella pyogenes, which has been directly linked to a higher risk of CE 21 days postpartum (10). T. pyogenes is a Gram-positive, opportunistic rod that causes purulent and necrotic lesions (11). Its pathogenicity in the endometrium stems from its pathogenic factor, pyolysin, which disrupts the endometrial barrier by its cytolytic activity and activates an inflammatory process in the endometrium (12). Routine treatment of CE includes parenteral application of prostaglandins or intrauterine application of antibiotics, for example, cephapirin (13). However, due to emerging antimicrobial resistance, there is a need for alternative treatment options or for reducing antibiotic use (14).

One already applied alternative is intrauterine infusion with diluted polyvinylpyrrolidone-iodine (PVP) (15). However, it is not entirely clear whether this treatment is fully beneficial. While in vitro studies show significant cytotoxic effects (16), in vivo testing on successful insemination rates suggests only transient inflammation of the uterus with subsequent benefits to the endometrium (17, 18). It shows antimicrobial properties through the biochemically active, free I2, which maintains an equilibrium with the I2 bound to polyvinylpyrrolidone (19). I2 acts oxidatively at different sites in the bacterium, which denatures and deactivates affected biomolecules and makes it hard for resistance to develop due to the broad possibility of points to attack (20, 21).

In equine medicine, some studies have examined the efficacy of N-acetylcysteine (NAC) in mares with endometritis. While endometrial integrity was preserved, there were no significant effects of intrauterine NAC-infusion on fertility (22). NAC originates from the acetylation of the amino acid L-cysteine and has many mechanisms of action, such as scavenging oxidants, replenishing glutathione, reducing disulfides, and, more recently, sulfane–sulfur effects (23). Various studies have shown its antibacterial and antibiofilm properties in ophthalmology, odontology, and against general pathogens on the skin (2427).

Methylglyoxal (MGO) is an active component of manuka honey and its leading antibacterial agent (28). Manuka honey is exclusively produced by the nectar of Leptospermum scoparium, a plant that is native to New Zealand and Southeast Australia, and shows extraordinarily high contents of MGO (29). Many studies show MGO’s ability to inhibit the growth of different bacteria, including multidrug-resistant bacteria (3032). It unfolds its antibacterial properties by disrupting the cell membrane of both Gram-positive and Gram-negative bacteria and inhibiting the formation of fimbriae and flagella (33). Manuka honey finds its use in veterinary medicine as an additive to wound dressings to promote wound healing and avoid infection (34).

N-chlorotaurine (NCT) is a derivative of the amino acid taurine, which is produced in the body by granulocytes and monocytes during the respiratory burst (35). It has also been synthesized as a sodium salt, which shows benefits in handling (35). Anich et al. showed NCT’s ability to inhibit the growth of multidrug-resistant bacteria and proved its efficacy was as high as against non-resistant bacteria (36). The evasion of resistance is due to the oxidizing and chlorinating effects that NCT has on multiple bacterial targets (37).

In this study, the antibacterial efficacy and cytotoxic effects of PVP, NAC, MGO, and NCT were evaluated against T. pyogenes and primary bovine endometrial epithelial cells to screen these substances for concentrations that are both effective and tolerable, since they have previously shown antibacterial properties. Potential concentrations serve as the basis for further ex vivo and/or in vivo experiments to identify applicable alternative treatments for bovine clinical endometritis, thereby minimizing or even excluding antibiotic use.

2 Materials and methods

2.1 Ethics statement

In Germany, this project does not require ethical clearance because the organs used were obtained from an abattoir. No animals were used or killed for the purpose of obtaining organs or bacteria. They were slaughtered for consumption, and the uteri made available were a byproduct of this process.

2.2 Bacterial isolation

Next to the reference bacterium T. pyogenes DSM 20594 from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, T. pyogenes isolates were obtained by sampling uteri from a local abattoir. When a uterus showed signs of inflammation and mucopurulent or purulent discharge upon opening its horns with sterile scissors, a cotton swab was taken out of each horn individually and used for a fractioned smear on Columbia sheep blood agar (Oxoid, Wesel, Germany). After 24 h of incubation at 37 °C and 5% CO2, colonies morphologically similar to T. pyogenes were subcultured on Columbia sheep blood agar for an additional 24 h. These subcultures were identified using matrix-assisted laser desorption/ionization–time of flight (MALDI–TOF). When T. pyogenes was identified, it was frozen and stored at −70 °C. Eight isolates were gained using this method.

2.3 Microdilution assay

For the microdilution assay, T. pyogenes was grown on Columbia sheep blood agar for 48 to 72 h and suspended in 0.9% saline solution at an optical density of 1.0 McFarland units. The test substances were dissolved and diluted in Micronaut-H-medium (Bruker, Bremen, Germany) at concentrations of 5.0–6.75 mg/mL for PVP (Sigma–Aldrich, Steinheim, Germany; 0.25 mg/mL per dilution step), 2.0–2.7 mg/mL for NAC (Sigma–Aldrich, Steinheim, Germany; 0.1 mg/mL per dilution step), 0.1–0.8 mg/mL for MGO (Sigma–Aldrich, Steinheim, Germany; 0.1 mg/mL per dilution step), and 1.0–3.5 mg/mL for NCT (Alchemist, Stuttgart, Germany; 0.25 mg/mL per dilution step). On a U-bottom 96-well plate (Greiner, Frickenhausen, Germany), 90 μL of medium with test substance or pure medium were mixed with either 10 μL of bacterial suspension (for positive control in medium and for the testing in medium with diluted test substance) or 10 μL of saline solution (negative control for medium and medium with test substance). After an incubation time of 48 h, the first concentration of test substance that showed no bacterial growth by visual inspection was considered the minimal inhibitory concentration (MIC) as defined by the Clinical and Laboratory Standards Institute (CLSI). For each of the nine isolates, the microdilution assay was repeated 6 times in biological replicates.

2.4 Bovine endometrial epithelial cell isolation

Bovine endometrial epithelial cells (BEEC) were isolated using a modified protocol from Nongbua et al. (38). Uteri from at least 24-month-old Holstein Friesian cows were obtained from a local abattoir and transported for approximately 2 h on ice. In the laboratory, the uteri were examined to rule out macroscopic infection or inflammation, and the cycle stages were determined by reviewing the ovaries as previously described (39). Only healthy uteri in the cycle stage I were used for further preparations. First, both uterine horns were opened with sterile scissors, and the endometrium was cut out into small pieces (approximately 3 mm) utilizing sterile small forceps and scissors. The endometrial pieces were transferred into digestion medium containing 250 U/mL collagenase IV (Sigma–Aldrich, Steinheim, Germany), 1,000 U/mL hyaluronidase (Roth, Karlsruhe, Germany) and 2% bovine serum albumin (BSA, Sigma–Aldrich, Steinheim, Germany) in Dulbecco’s phosphate buffered solution (DPBS, Roth, Karlsruhe, Germany) and digested for 2.5 h in a water bath at 39 °C. Every 30 min, the suspension was vortexed for 1–2 s. After incubation, the suspension was filtered using, first, gaze to remove larger tissue chunks, and then a 100μm filter (Sarstedt, Nümbrecht, Germany) for filtering the cell suspension. The suspension was then centrifuged for 5 min at 150 g and resuspended in culture medium containing 10% fetal calf serum (Bio&SELL, Feucht, Germany), 5ml insulin–transferrin–selenium (ITS, Gibco, Carlsbad, CA, USA), 50 U/mL penicillin (Gibco, Carlsbad, CA, USA), 50 μg/mL streptomycin (Gibco, Carlsbad, California, USA), 10 μg/mL gentamicin (Roth, Karlsruhe, Germany), and 2,5 μg/mL amphotericin B (Bio&SELL, Feucht, Germany) in Dulbecco’s modified eagle medium + Ham’s 12 medium (DMEM F12) supplemented with 2mM glutamine (Roth, Karlsruhe, Germany). The cell suspension was transferred into a 75 cm2 cell culture flask (Greiner, Frickenhausen, Germany) and incubated at 37 °C and 5% CO2.

To ensure pure epithelial cell cultures, the method of selective passaging was adapted from Kelly et al. (40). BEEC were passaged at about 90% confluency by first detaching stromal cells with accutase (Bio&SELL, Feucht, Germany) for 5 min, washing them out with DPBS and discarding them, and then detaching the epithelial cells with 0.25%/0.02% trypsin/ethylenediaminetetraacetate (EDTA, Biochrom, Berlin, Germany) for about 10 min and seeding them at 100,000–500,000 cells per flask. At passage 3, the culture was almost free of stromal cells as proven by fluorescent immunocytochemistry.

2.5 Fluorescent immunocytochemistry

To identify the cells as either epithelial or stromal, fluorescent immunocytochemistry was performed on each isolation at passage 3 or higher. In four wells of a 24-well plate (Greiner, Frickenhausen, Germany), sterile glass coverslips (Roth, Karlsruhe, Germany) were placed, and 10,000 cells/well were seeded onto them. Each well will have one of the following staining: (1) cytokeratin, (2) vimentin, (3) a combination of cytokeratin and vimentin, and (4) negative control. The following day, the cell culture medium was removed, and the wells were washed twice with 300 μL/well phosphate-buffered solution (PBS). Then, cells were fixated with 300 μL/well of an ice-cold 1:1 mixture of acetone (Sigma–Aldrich, Steinheim, Germany) and methanol (Avantor Performance Materials Poland, Gliwice, Poland) for 5 min. As a next step, cells were blocked at room temperature with 300 μL/well of a blocking solution consisting of 0.25% Triton X-100 (Sigma–Aldrich, Steinheim, Germany) and 1% BSA in PBS. After removing the blocking solution, the first antibody, a primary mouse pan-anticytokeratin (C11; Novus Biologicals, Wiesbaden, Germany), was diluted 1:100 in the blocking solution and added to wells 1 and 3 at 150 μL/well. Wells 2 and 4 were blocked by 150 μL/well blocking solution. Following a 1h incubation at 37 °C, all wells were washed twice with 300 μL/well PBS for 5 min. The second antibody, a fluorescein-marked secondary goat F(ab)2-anti-mouse-antibody (AbD serotec, Puchheim, Germany), was diluted 1:200 in blocking solution and added to wells 1, 3, and 4 at 150 μL/well. To well 2, a 150-μl blocking solution was added and the plate incubated at 37 °C for 30 min. All wells were washed twice after the first antibody. After the third antibody, a cyanin3-marked monoclonal mouse anti-vimentin antibody (Sigma, Steinheim, Germany), was diluted to 1:200 in blocking solution and added to wells 2 and 3 at 150 μL/well. Well 1 and 4 were blocked by 150 μL/well blocking solution, the plate was incubated at 37 °C for another 30 min, and all wells were washed twice as in previous steps. At last, the coverslips were attached to microscope slides and cell nuclei were stained using Fluoroshield™ DAPI (Sigma, Steinheim, Germany). The staining was evaluated by fluorescent microscopy with the Zeiss ObserverZ1/1 microscope and Zeiss Zen 3.8 software (Carl Zeiss Microscopy, Oberkochen, Germany).

2.6 Cytotoxicity assays

For cytotoxicity testing, BEEC were seeded onto F-bottom 96-well-plates (Greiner, Frickenhausen, Germany) at a density of 10,000 cells/well in culture medium. Treatments included PVP (5.75 and 6 mg/mL), NAC (2.4 and 2.5 mg/mL), MGO (0.4 and 0.5 mg/mL), and NCT (2.25 and 2.5 mg/mL), which were dissolved and diluted in culture medium, and pure culture medium as a control. These concentrations were chosen after an initial screening of MIC of the reference bacterium and represent the median MIC itself as well as one concentration just above the MIC. For the neutral red assay and bovine interleukin 6 (IL-6) enzyme-linked immunosorbent assay (ELISA) cells were also treated with 1 μg/mL lipopolysaccharide O111: B4 (LPS, from Escherichia coli, Sigma–Aldrich, Steinheim, Germany) as well as 1 and 10 μg/mL peptidoglycan (PGN, from Staphylococcus aureus, Sigma–Aldrich¸ Steinheim, Germany). Both the crystal violet staining and the neutral red uptake assay were undertaken in six biological replicates, each representing an independent cell isolation from different animals, and eight technical replicates. Relative proliferation and viability values were calculated by the following equation (Equation 1):

Percentage ( % ) of control = OD 570 nm of well × 100 mean OD 570 nm of control wells     (1)

2.6.1 Crystal violet staining assay

To determine cell proliferation, a modified crystal violet staining assay (41, 42) was performed. Notably, 24 h after seeding, cells were treated as described above with 100 μL of each solution per well and incubated for an additional 24 h. After removal of the treatments, cells were fixated for 20 min using 100 μL/well 2% glutaraldehyde (Roth, Karlsruhe, Germany) in PBS and stained with 100 μL/well 0.1% crystal violet dye (Roth, Karlsruhe, Germany) in distilled water for 30 min. After washing the wells with 300 μL/well distilled water and air-drying for about 2 h, crystal violet was extracted for 1 h on an orbital shaker (SO3, Stuart Scientific, Stone, Great Britain) at 250 rpm using 50 μL/well 2% tergitol in distilled water (Sigma–Aldrich, Steinheim, Germany) and the optical density was measured in an MRX-reader (Microplate-reader Multiscan FC, Thermo Scientific, Waltham, MA, United States) at 570 nm. Each step after incubation was performed at room temperature.

2.6.2 Neutral red uptake assay

To determine cell viability, a neutral red uptake assay was performed. Notably, 72 h after seeding, cells reached confluency and were treated as mentioned above for 24 h. Supernatants were collected and stored at −20 °C for later usage in a bovine IL-6 ELISA. Neutral red stock solution (1 mg/mL in distilled water, AppliChem, Darmstadt, Germany) was diluted 1:100 in cell culture medium and incubated at 37 °C for 30 min. After centrifuging for 10 min at 1,500 g, 200μl neutral red solution was added to each well, and the plate was incubated for 3 h in the incubator. After removal of the neutral red solution, the plate was laid upside down for approximately 2 min to dry. Then, 100 μL of a solution containing 1% calcium chloride (Merck, Darmstadt, Germany) and 0.5% formaldehyde (Merck, Darmstadt, Germany) in distilled water was added to each well and removed. At last, 100 μL of a solution consisting of 1% acetic acid (AppliChem, Darmstadt, Germany) and 50% ethanol (CG-Chemikaliengesellschaft, Laatzen, Germany) in distilled water was added to each well and shaken on an orbital shaker for 30 s. After an incubation in the fridge for 10 min, the optical densities were measured using an MRX-reader at 570 nm. The assay was executed according to the International Organization for Standardization (ISO) DIN Norm 10,993–5-2009(E).

2.6.3 Bovine IL-6 enzyme-linked immunosorbent assay

For the bovine IL-6 ELISA, the DuoSet™ ELISA Development System with additional DuoSet™ Ancillary Kit 3 (R&D Systems, Minneapolis, Minnesota, United States) was used according to the manufacturer’s protocols. Supernatants were collected from confluent cells after 24 h of treatment and frozen at −20 °C. The supernatants from the LPS treatment were diluted to 1:10.

2.7 Statistical analysis

All statistical analyses were performed using the GraphPad Prism Software (version 10.4.1 (627), GraphPad Software, Inc., Boston, MA, United States). Descriptive statistics were applied to the MIC values of all T. pyogenes isolates. Cytotoxicity data were analyzed using a Friedman test followed by Dunn’s multiple comparisons test comparing each treatment with the culture medium control. Differences were considered statistically significant at p ≤ 0.05.

3 Results

3.1 Minimal inhibitory concentration

For all four substances (PVP, NAC, MGO, and NCT), the MIC values of the reference bacterium and eight T. pyogenes isolates were determined. Altogether, the median MIC value for PVP was at 5.75 mg/mL, with a range of 1.5 mg/mL and an interquartile range (IQR) from 5.5 to 5.75 mg/mL. For NAC, the median was at 2.5 mg/mL with a range of 0.7 mg/mL and an IQR from 2.4 to 2.6 mg/mL. MGO showed a median MIC of 0.2 mg/mL with a range of 0.3 mg/mL and an IQR from 0.2 to 0.3 mg/mL. Finally, NCT had a median MIC of 2 mg/mL with a range of 1.5 mg/mL and an IQR from 1.75 to 2.25 mg/mL.

3.2 Fluorescent immunocytochemistry

In addition to morphological control in light microscopy, all cell isolations used for cytotoxicity testing were stained by fluorescent immunocytochemistry to ensure that only epithelial cells were included in testing. Staining was performed at passage 3 or 4 and resulted in the identification of pure epithelial endometrial cells, as exemplified by Figure 1.

Figure 1
Three micrographs labeled A, B, and C depict epithelial cells with fluorescence staining. Images A and C show cells with green and blue fluorescence, indicating the presence of specific proteins or structures. Image B displays cells with orange and blue fluorescence. Scale bars are marked at 100 micrometers.

Figure 1. BEECs were stained with (A) FITC (green) for epithelial cells, (B) Cy3 (orange) for stromal cells individually, as well as (C) on the same slide, and DAPI (blue) for cell nuclei on all slides.

3.3 Cytotoxicity assessment

In proliferation and viability testing, PVP, NAC, MGO, and NCT generated the following effects on BEEC compared with cells treated with culture medium as the control (Figure 2). Only treatment with PVP and NCT at their respective concentrations resulted in significantly lower proliferation and viability compared to control cells. Additionally, MGO significantly reduced cell viability at a concentration of 0.5 mg/mL.

Figure 2
Box plots showing data for two conditions, labeled A and B, comparing percent of control across various treatments: PVP, NAC, MGO, NCT, and Control. Significant differences are indicated by asterisks, with varying medians and ranges, demonstrating differing effects of treatments compared to the control group.

Figure 2. Influence of two concentrations of each tested substance on (A) proliferation and (B) viability of BEEC. The x-axis shows antibacterial substances in their tested concentrations; the y-axis shows cell proliferation/viability as the percentage of control cells. The data is presented as boxplots with min/max-whiskers, dots stand for the mean of each biological replicate (tested in an 8-fold technical replicate), and the overall mean is indicated by a +. The dotted line represents the 70% limit for cytotoxicity testing according to ISO 10993-5:2009. Data were analyzed by the Friedmann test following Dunn’s multiple comparisons test of each treatment with the culture medium control. Significant differences between treated and control cells are depicted by asterisks: *p ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001. n = 6.

The cells treated with PVP showed a proliferation of 22.7 ± 8.7% at a concentration of 5.75 mg/mL and 25.0 ± 9.4% at a concentration of 6.0 mg/mL. The viability values were 17.7 ± 4.3% and 17.5 ± 3.6%, respectively. When cells were treated with 2.5 and 2.6 mg/mL NAC, proliferation compared to control was 66.9 ± 12.6% and 62.4 ± 12.2% and viability was 92.3 ± 4.1% and 90.2 ± 4.8%. The cells treated with 0.4 and 0.5 mg/mL MGO showed proliferation values of 55.0 ± 9.5% and 53.7 ± 10.2%, respectively, whereas viability decreased to 21.7 ± 6.8% and 18.3 ± 2.2%. NCT at the concentrations of 2.25 and 2.5 mg/mL reduced proliferation to 26.7 ± 4.8% and 28.4 ± 4.8% and viability to 14.4 ± 1.8% and 15.5 ± 1.5%.

3.4 IL-6 release

Results of the bovine IL-6 ELISA show that, in contrast to NAC (50.9 ± 36.3 for 2.5 mg/mL; 43.1 ± 16.2 pg./mL for 2.6 mg/mL) treatment, with PVP, MGO, and NCT led to no detectable release of IL-6 (Figure 3). Treatment with LPS resulted in IL-6 release up to 1,366 pg/mL (629 ± 495 pg./mL). Cells treated with cell culture medium as a control released no detectable IL-6 except for one biological replicate, which released 193.9 pg./mL. There were no significant differences between the control and the treatments, or between 1 μg/mL LPS and the treatments.

Figure 3
Bar chart showing IL-6 levels in picograms per milliliter for various treatments, including PVP, NAC, MGO, NCT, and controls. Significant elevation in IL-6 is observed with LPS 1 microgram per milliliter compared to others.

Figure 3. IL-6 release of two concentrations of each tested substance, as well as LPS at 1 μg/mL, PGN at 1 μg/mL and 10 μg/mL, and control (medium). The x-axis shows all treatments in their tested concentrations; the y-axis shows the release of IL-6 in pg/ml. The data are presented as boxplots with minimum/maximum whiskers, and dots represent each measured value in the bovine IL-6 ELISA assay (six biological replicates). Data were analyzed by the Friedman test following Dunn’s multiple comparisons test for each treatment with the culture medium control and LPS 1 μg/mL. No significant differences could be detected. n = 6.

4 Discussion

In this study, T. pyogenes was isolated from organs of slaughtered cows. While organs were selected based on apparent inflammation and discharge, it is hard to determine whether these findings were clinically relevant to the affected cow. However, T. pyogenes was found mostly in cows with CE in comparison to healthy cows or cows with subclinical endometritis (43). Considering this, any involvement of T. pyogenes would be significant for treating a possible inflammation, and any isolated T. pyogenes would yield results applicable to studying MICs.

The only substance that has been tested with T. pyogenes for its MIC before is PVP (16). The MIC value was 1.25% in a broth microdilution with tryptone soy broth, which is more than twice the value reported in this study. This could be due to differences in setups used across the tested concentrations. While Thongrueang et al. used 10-fold serial dilutions, this setup included 0.25 mg/mL steps, screening for a more precise MIC rather than a general direction, which, in this case, would support the conclusion that the findings do not refute one another. In contrast, Mido et al. (15) found concentrations of 0.5 and 2.0% PVP to be effective against bacteria from the uterus in vitro as well as in vivo.

While there was no published research found on the effect of NAC against T. pyogenes, there are studies on its efficacy against other pathogens, such as different Staphylococcus and Streptococcus spp., E. coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae (24, 4446). Overall, MIC ranged from 1.56 to 10 mg/mL, indicating that NAC has sufficient antibacterial activity at those concentrations. Our findings fall within the range of previous studies at 2.5 mg/mL for T. pyogenes, and therefore can be considered to be realistic results. In addition, Bohn et al. even found the same MIC at 2.5 mg/mL for two multiresistant and one sensitive isolate of Staphylococcus pseudintermedius (47).

MIC determination for MGO was also not previously performed for T. pyogenes. A study conducted on multidrug-resistant P. aeruginosa in agar dilution testing observed MIC values for methylglyoxal of 128–512 μg/mL (30). Green et al. detected similar concentrations in a broth microdilution assay with S. aureus, Enterococcus faecalis, E. coli, and P. aeruginosa (28) and showed that honey’s antibacterial properties correlate with its MGO content. In this study, MGO concentrations of 0.2 mg/mL were found to inhibit bacterial growth, making them comparable to the aforementioned studies.

There is currently no data available on any MIC for NCT. However, in biofilm reduction studies, 1% NCT showed a significant reduction of biofilms (48, 49). In this study, NCT was effective against T. pyogenes at lower concentrations (2 mg/mL), likely because the antibacterial substances function more effectively when they do not have to breach a biofilm first.

Overall, the concentrations were determined by broth microdilution in a medium specifically adapted for T. pyogenes. It is to be expected that under these in vitro conditions, different results are obtained than in in vivo testing, which is why concentration adaptation needs to happen in animal experiments. In vitro testing, however, shows a general direction for the applicability of the tested substances, reducing animal testing to only the most promising substances and concentrations.

Concentrations for cytotoxicity testing were chosen based on preliminary MIC results to show that effective antibacterial concentrations could be tolerated by the endometrial epithelium. PVP has already been shown to be cytotoxic at low concentrations (50). For bovine endometrial epithelial cells, only 1 h of exposure to 0.025% PVP led to a significant loss of viability (16). In this study, PVP was again tested to undermine the cytotoxic effect of PVP, since in practice it is still commonly used as a diluted irrigation to flush the uteri of cows with CE (15). In a study on corneal toxicity, Chen et al. found one mechanism of cytotoxicity of PVP to be an increase in oxidative stress (51). Also studying corneal toxicity, Chou et al. saw cytotoxicity mainly due to the halt of intracellular esterase activities and lowered cell membrane integrity (52).

In mares, intrauterine administration of NAC (5 and 3.3%) did not result in any adverse effects on the endometrium (22, 53). In this study, concentrations of 2.5 and 2.6 mg/mL were much lower than those tested in vivo and, as expected, were tolerated well by the BEEC. Especially for NAC, further research on ex vivo and in vivo models seems therefore promising. Another aspect that could be studied is the possible mucolytic effects on uterine discharge.

The effects of MGO on BEEC have not been studied. However, it showed cytotoxic effects against tumor cells due to oxidative stress, resulting in apoptosis, which made it an interesting topic in anti-tumor therapy (54, 55). But there are many more pathways of cytotoxicity to be found in the literature, for example, dysfunction of SERCA pumps, mitochondria-dependent apoptosis, and endoplasmic reticulum stress-associated production of reactive oxygen species (5660). The tested concentrations in this study confirm cytotoxicity in BEEC as well. Since Manuka Honey itself does not show such drastic cytotoxic effects, with methylglyoxal only being one of its many biologically active components, further research into Manuka Honey would be interesting, even with the challenges of standardization in this natural product (29).

In this study, NCT was not well tolerated. This stands in contrast to previous studies conducted on different cell lines, which reported good tolerability of NCT at concentrations of 0.01–1% (61, 62). While the in vitro cytotoxicity results in this study indicate that NCT might not be a well-suited antibacterial alternative, other research shows that NCT was often tolerated better in vivo than it was in vitro (35, 61, 63). This could have different reasons, such as a more robust barrier of cells built in vivo, protection by bodily fluids or mucus, or shorter exposure times. Considering this, NCT seems a noteworthy candidate for further testing in its antibacterial concentrations.

IL-6 is a pro-inflammatory cytokine in the context of CE (4). Therefore, the effects of PVP, NAC, MGO, and NCT on their release were investigated to draw conclusions on whether these substances could modulate the immune response in the endometrium. Treatment with PVP, MGO, and NCT did not result in detectable IL-6 in the collected supernatants. However, it must be noted that the concentrations used were already cytotoxic and therefore the release of cytokines could not be expected. When treated with NAC, cells had a higher survival rate, which explains the higher IL-6 concentration in those supernatants compared to the other treatments. Due to the high variability in IL-6 release in the positive control with LPS, it is hard to contextualize this IL-6 concentration after treatment with NAC. However, it also did not induce a significantly higher release of IL-6 than the control, which suggests no significant proinflammatory response was mounted after NAC treatment. Previously, NAC has shown anti-inflammatory effects (23, 64), so the IL-6 release could be non-significant compared to properly mounted reactions to a positive control. This limitation, arising from two biological replicates, showing no detectable IL-6, could have several explanations. While IL-6 is a relatively stable analyte, there are conflicting study results on optimal storage temperature and the number of possible freeze/thaw cycles (65). A problem with its stability in these particular replicates could therefore be one explanation. Another explanation could be the lack of predictability of the primary cell culture in this in vitro model. Even though this was not a problem when investigating proliferation and viability, intracellular pathways might be inadequate to mount a reliable immune response. Cytotoxicity, as an explanation for the absence of detectable IL-6, can be ruled out, as the concentrations of LPS and PGN used were tested for tolerability by the cells before conducting the ELISA.

One challenge in this study was the very low success rate in endometrial epithelial cell isolations. Only 25% of all isolations provided pure and viable epithelial cell culture that could be passaged up to 6 times or more, and were taken into consideration for cytotoxicity testing. Failed isolations were mostly due to stromal cells outgrowing the epithelial cells irretrievably or epithelial cell death before reaching passage 3. Only successful cell isolations could be used for the cytotoxicity assays, thus providing reliable data. For future experiments, a refined isolation method would be essential if a high screening rate is required.

In summary, the results of this research provide greater insight into four known antibacterial substances for the treatment of bovine clinical endometritis. All of them performed well in broth microdilution assays against T. pyogenes. However, more testing by, for example, time-killing assays or determination of minimal bactericidal concentrations would improve possible dosages that could be screened in animal experiments. Another interesting scope would be the effect of these substances on the endometrial immune response and on the activation of intracellular cascades, as has been reported for other cells (66). In addition, infection assays with an ex vivo endometrial model would provide a better understanding of possible protection of tissue against bacterial infection, possibly outweighing the cytotoxic effects shown for PVP, MGO, and NCT when tissue is left in a unit, as would be the case for endometrial explants (67). For future practical relevance, all substances could be used as an easily applicable solution for intrauterine infusion and flushing, as is already the case for PVP (15). For those, stability testing would be necessary before commercial availability. Another approach could be the combination with classic antibiotics to identify possible synergistic and/or antagonistic effects (6871).

5 Conclusion

All tested alternatives to antibiotics appear applicable based on these in vitro results, given their antibacterial efficacy against T. pyogenes. However, the cytotoxic effects of PVP, MGO, and NCT on BEEC show that more research is needed to determine whether those effects translate into an ex vivo/in vivo setting and would therefore eliminate those substances as viable intrauterine treatment options.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

Ethical approval was not required for the study involving animals in accordance with the local legislation and institutional requirements because organs were obtained from animals that were not killed in relation to this study.

Author contributions

DP: Methodology, Writing – review & editing, Investigation, Formal analysis, Writing – original draft, Visualization. HO: Methodology, Writing – review & editing, Writing – original draft. JM: Conceptualization, Writing – review & editing, Methodology, Writing – original draft, Supervision.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This study is self-funded. We acknowledge financial support by the Open Access Publication Fund of the University of Veterinary Medicine Hannover, Foundation.

Acknowledgments

The authors would like to thank Caroline Groß and Viktoria Nepke for their technical assistance.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Sheldon, IM, Lewis, GS, LeBlanc, S, and Gilbert, RO. Defining postpartum uterine disease in cattle. Theriogenology. (2006) 65:1516–30. doi: 10.1016/j.theriogenology.2005.08.021,

PubMed Abstract | Crossref Full Text | Google Scholar

2. Pascottini, OB, Aurich, C, England, G, and Grahofer, A. General and comparative aspects of endometritis in domestic species: a review. Reprod Domest Anim. (2023) 58:49–71. doi: 10.1111/rda.14390

Crossref Full Text | Google Scholar

3. LeBlanc, SJ, Duffield, TF, Leslie, KE, Bateman, KG, Keefe, GP, Walton, JS, et al. Defining and diagnosing postpartum clinical endometritis and its impact on reproductive performance in dairy cows. J Dairy Sci. (2002) 85:2223–36. doi: 10.3168/jds.S0022-0302(02)74302-6,

PubMed Abstract | Crossref Full Text | Google Scholar

4. Sheldon, IM, Cronin, JG, and Bromfield, JJ. Tolerance and innate immunity shape the development of postpartum uterine disease and the impact of endometritis in dairy cattle. Annual Rev Animal Biosci. (2019) 7:361. doi: 10.1146/annurev-animal-020518-115227,

PubMed Abstract | Crossref Full Text | Google Scholar

5. Pascottini, OB, and LeBlanc, SJ. Modulation of immune function in the bovine uterus peripartum. Theriogenology. (2020) 150:193–200. doi: 10.1016/j.theriogenology.2020.01.042

Crossref Full Text | Google Scholar

6. Ji, G, Zhang, J, Feng, X, Sheng, H, Hu, H, Li, F, et al. Analysis of blood biochemistry and non-targeted metabolomics of endometritis in dairy cows. Anim Reprod Sci. (2024) 264:107460. doi: 10.1016/j.anireprosci.2024.107460,

PubMed Abstract | Crossref Full Text | Google Scholar

7. LeBlanc, SJ. Interactions of metabolism, inflammation, and reproductive tract health in the postpartum period in dairy cattle. Reprod Domest Anim. (2012) 47:18–30. doi: 10.1111/j.1439-0531.2012.02109.x,

PubMed Abstract | Crossref Full Text | Google Scholar

8. Galvão, KN, Bicalho, RC, and Jeon, SJ. Symposium review: the uterine microbiome associated with the development of uterine disease in dairy cows. J Dairy Sci. (2019) 102:11786–97. doi: 10.3168/jds.2019-17106,

PubMed Abstract | Crossref Full Text | Google Scholar

9. Földi, J, Kulcsár, M, Pécsi, A, Huyghe, B, de Sa, C, Lohuis, JA, et al. Bacterial complications of postpartum uterine involution in cattle. Anim Reprod Sci. (2006) 96:265–81. doi: 10.1016/j.anireprosci.2006.08.006,

PubMed Abstract | Crossref Full Text | Google Scholar

10. Wagener, K, Grunert, T, Prunner, I, Ehling-Schulz, M, and Drillich, M. Dynamics of uterine infections with Escherichia coli, Streptococcus uberis and Trueperella pyogenes in post-partum dairy cows and their association with clinical endometritis. Vet J. (2014) 202:527–32. doi: 10.1016/j.tvjl.2014.08.023,

PubMed Abstract | Crossref Full Text | Google Scholar

11. Rzewuska, M, Kwiecień, E, Chrobak-Chmiel, D, Kizerwetter-Świda, M, Stefańska, I, and Gieryńska, M. Pathogenicity and virulence of Trueperella pyogenes: a review. Int J Mol Sci. (2019) 20:2737. doi: 10.3390/ijms20112737,

PubMed Abstract | Crossref Full Text | Google Scholar

12. Amos, MR, Healey, GD, Goldstone, RJ, Mahan, SM, Düvel, A, Schuberth, H-J, et al. Differential endometrial cell sensitivity to a cholesterol-dependent Cytolysin links Trueperella Pyogenes to uterine disease in Cattle1. Biol Reprod. (2014) 90:54. doi: 10.1095/biolreprod.113.115972,

PubMed Abstract | Crossref Full Text | Google Scholar

13. Barański, W, Baryczka, A, Zduńczyk, S, Tobolski, D, and Janowski, T. Prevalence of subclinical endometritis in dairy cows that recovered after treatment of clinical endometritis with Cephapirin and Pgf2α. Theriogenology. (2022) 192:166–71. doi: 10.1016/j.theriogenology.2022.08.031,

PubMed Abstract | Crossref Full Text | Google Scholar

14. Kasimanickam, V, Kasimanickam, M, and Kasimanickam, R. Antibiotics use in food animal production: escalation of antimicrobial resistance: where are we now in combating AMR? Med Sci (Basel). (2021) 9:14. doi: 10.3390/medsci9010014,

PubMed Abstract | Crossref Full Text | Google Scholar

15. Mido, S, Murata, N, Rawy, MS, Kitahara, G, and Osawa, T. Effects of intrauterine infusion of povidone-iodine on endometrial cytology and bacteriology in dairy cows with clinical endometritis. J Vet Med Sci. (2016) 78:551–6. doi: 10.1292/jvms.15-0412,

PubMed Abstract | Crossref Full Text | Google Scholar

16. Thongrueang, N, Liu, SS, Hsu, HY, and Lee, HH. An in vitro comparison of antimicrobial efficacy and cytotoxicity between povidone-iodine and chlorhexidine for treating clinical endometritis in dairy cows. PLoS One. (2022) 17:e0271274. doi: 10.1371/journal.pone.0271274,

PubMed Abstract | Crossref Full Text | Google Scholar

17. Yoshida, R, Kitahara, G, and Osawa, T. Intrauterine infusion of povidone-iodine: its effect on the endometrium and subsequent fertility in postpartum dairy cows. J Vet Med Sci. (2020) 82:926–34. doi: 10.1292/jvms.20-0165,

PubMed Abstract | Crossref Full Text | Google Scholar

18. Monstrey, SJ, Govaers, K, Lejuste, P, Lepelletier, D, and de Ribeiro Oliveira, P. Evaluation of the role of povidone-iodine in the prevention of surgical site infections. Surg Open Sci. (2023) 13:9–17. doi: 10.1016/j.sopen.2023.03.005,

PubMed Abstract | Crossref Full Text | Google Scholar

19. Gottardi, W. Iodine and disinfection: theoretical study on mode of action, efficiency, stability, and analytical aspects in the aqueous system. Arch Pharm (Weinheim). (1999) 332:151–7.

Google Scholar

20. Meehan, JP. Dilute povidone-iodine irrigation: the science of molecular iodine (I2) kinetics and its antimicrobial activity. JAAOS - J American Acad Orthopaedic Surgeons. (2025) 33:65–73. doi: 10.5435/jaaos-d-24-00471,

PubMed Abstract | Crossref Full Text | Google Scholar

21. Schreier, H, Erdos, G, Reimer, K, König, B, König, W, and Fleischer, W. Molecular effects of povidone-iodine on relevant microorganisms: an Electron-microscopic and biochemical study. Dermatology. (2009) 195:111–6. doi: 10.1159/000246043,

PubMed Abstract | Crossref Full Text | Google Scholar

22. Gores-Lindholm, AR, LeBlanc, MM, Causey, R, Hitchborn, A, Fayrer-Hosken, RA, Kruger, M, et al. Relationships between intrauterine infusion of N-acetylcysteine, equine endometrial pathology, neutrophil function, post-breeding therapy, and reproductive performance. Theriogenology. (2013) 80:218–27. doi: 10.1016/j.theriogenology.2013.03.026,

PubMed Abstract | Crossref Full Text | Google Scholar

23. Tieu, S, Charchoglyan, A, Paulsen, L, Wagter-Lesperance, LC, Shandilya, UK, Bridle, BW, et al. N-acetylcysteine and its immunomodulatory properties in humans and domesticated animals. Antioxidants. (2023) 12:1867. doi: 10.3390/antiox12101867,

PubMed Abstract | Crossref Full Text | Google Scholar

24. Walter, H, Verspohl, J, Meißner, J, Oltmanns, H, Geks, AK, and Busse, C. In vitro antimicrobial activity of N-acetylcysteine against pathogens most commonly associated with infectious keratitis in dogs and cats. Antibiotics. (2023) 12:559. doi: 10.3390/antibiotics12030559,

PubMed Abstract | Crossref Full Text | Google Scholar

25. Quah, SY, Wu, S, Lui, JN, Sum, CP, and Tan, KS. N-acetylcysteine inhibits growth and eradicates biofilm of Enterococcus Faecalis. J Endodont. (2012) 38:81–5. doi: 10.1016/j.joen.2011.10.004,

PubMed Abstract | Crossref Full Text | Google Scholar

26. Heun, F, Meißner, J, Schieder, AK, Ohnesorge, B, and Busse, C. Pantoea agglomerans in equine ulcerative keratitis: prevalence and comparative efficacy of four topical antiseptics. Vet Ophthalmol. (2025) 1–10. doi: 10.1111/vop.70044

Crossref Full Text | Google Scholar

27. Eroshenko, D, Polyudova, T, and Korobov, V. N-acetylcysteine inhibits growth, adhesion and biofilm formation of gram-positive skin pathogens. Microb Pathog. (2017) 105:145–52. doi: 10.1016/j.micpath.2017.02.030,

PubMed Abstract | Crossref Full Text | Google Scholar

28. Green, KJ, Lawag, IL, Locher, C, and Hammer, KA. Correlation of the antibacterial activity of commercial Manuka and Leptospermum honeys from Australia and New Zealand with methylglyoxal content and other physicochemical characteristics. PLoS One. (2022) 17:e0272376. doi: 10.1371/journal.pone.0272376,

PubMed Abstract | Crossref Full Text | Google Scholar

29. Wang, S, Qiu, Y, and Zhu, F. An updated review of functional ingredients of Manuka honey and their value-added innovations. Food Chem. (2024) 440:138060. doi: 10.1016/j.foodchem.2023.138060,

PubMed Abstract | Crossref Full Text | Google Scholar

30. Hayashi, K, Fukushima, A, Hayashi-Nishino, M, and Nishino, K. Effect of methylglyoxal on multidrug-resistant Pseudomonas aeruginosa. Front Microbiol. (2014) 5:180. doi: 10.3389/fmicb.2014.00180,

PubMed Abstract | Crossref Full Text | Google Scholar

31. Kilty, SJ, Duval, M, Chan, FT, Ferris, W, and Slinger, R. Methylglyoxal: (active agent of Manuka honey) in vitro activity against bacterial biofilms. Int Forum Allergy Rhinol. (2011) 1:348–50. doi: 10.1002/alr.20073,

PubMed Abstract | Crossref Full Text | Google Scholar

32. Afzal, RK, Khalid, F, Hannan, A, and Ahmed, SA. Methylglyoxal: antimicrobial activity against blood culture isolates of salmonella Typhi and other gram negative rods. Pak J Med Sci. (2019) 35:1110–4. doi: 10.12669/pjms.35.4.807,

PubMed Abstract | Crossref Full Text | Google Scholar

33. Rabie, E, Serem, JC, Oberholzer, HM, Gaspar, AR, and Bester, MJ. How methylglyoxal kills bacteria: an ultrastructural study. Ultrastruct Pathol. (2016) 40:107–11. doi: 10.3109/01913123.2016.1154914,

PubMed Abstract | Crossref Full Text | Google Scholar

34. Bischofberger, AS, Dart, CM, Perkins, NR, and Dart, AJ. A preliminary study on the effect of Manuka honey on second-intention healing of contaminated wounds on the distal aspect of the forelimbs of horses. Vet Surg. (2011) 40:898–902. doi: 10.1111/j.1532-950X.2011.00886.x,

PubMed Abstract | Crossref Full Text | Google Scholar

35. Gottardi, W, and Nagl, M. N-Chlorotaurine, a natural antiseptic with outstanding tolerability. J Antimicrob Chemother. (2010) 65:399–409. doi: 10.1093/jac/dkp466,

PubMed Abstract | Crossref Full Text | Google Scholar

36. Anich, C, Orth-Höller, D, Lackner, M, and Nagl, M. N-Chlorotaurine, a potent weapon against multiresistant Bacteria. J Appl Microbiol. (2021) 131:1742–8. doi: 10.1111/jam.15052,

PubMed Abstract | Crossref Full Text | Google Scholar

37. Arnitz, R, Sarg, B, Ott, HW, Neher, A, Lindner, H, and Nagl, M. Protein sites of attack of N-Chlorotaurine in Escherichia Coli. Proteomics. (2006) 6:865–9. doi: 10.1002/pmic.200500054,

PubMed Abstract | Crossref Full Text | Google Scholar

38. Nongbua, T, Guo, Y, Edman, A, Humblot, P, and Morrell, J. Effect of bovine seminal plasma on bovine endometrial epithelial cells in culture. Reprod Domest Anim. (2018) 53:85–92. doi: 10.1111/rda.13069,

PubMed Abstract | Crossref Full Text | Google Scholar

39. Ireland, JJ, Murphee, RL, and Coulson, PB. Accuracy of predicting stages of bovine estrous cycle by gross appearance of the Corpus Luteum1. J Dairy Sci. (1980) 63:155–60.

Google Scholar

40. Kelly, P, Barry-Reidy, A, Brewer, A, Meade, KG, and O’Farrelly, C. Improved filtration method to isolate pure populations of primary bovine endometrial epithelial and stromal cells for immunological studies. Vet Res Commun. (2020) 44:29–39. doi: 10.1007/s11259-020-09770-3,

PubMed Abstract | Crossref Full Text | Google Scholar

41. Gillies, RJ, Didier, N, and Denton, M. Determination of cell number in monolayer cultures. Anal Biochem. (1986) 159:109–13.

Google Scholar

42. Saotome, K, Morita, H, and Umeda, M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol in Vitro. (1989) 3:317–21.

Google Scholar

43. Paiano, RB, Moreno, LZ, Gomes, VTM, Parra, BM, Barbosa, MR, Sato, MIZ, et al. Assessment of the Main pathogens associated with clinical and subclinical endometritis in cows by culture and Maldi-Tof mass spectrometry identification. J Dairy Sci. (2022) 105:3367–76. doi: 10.3168/jds.2021-20642,

PubMed Abstract | Crossref Full Text | Google Scholar

44. Petkova, T, Rusenova, N, Danova, S, and Milanova, A. Effect of N-acetyl-L-cysteine on activity of doxycycline against biofilm-forming bacterial strains. Antibiotics. (2023) 12:1187. doi: 10.3390/antibiotics12071187,

PubMed Abstract | Crossref Full Text | Google Scholar

45. Chan, WY, Khazandi, M, Hickey, EE, Page, SW, Trott, DJ, and Hill, PB. In vitro antimicrobial activity of seven adjuvants against common pathogens associated with canine otitis externa. Vet Dermatol. (2019) 30:133–e38. doi: 10.1111/vde.12712,

PubMed Abstract | Crossref Full Text | Google Scholar

46. De Angelis, M, Mascellino, MT, Miele, MC, Al Ismail, D, Colone, M, Stringaro, A, et al. High activity of N-acetylcysteine in combination with beta-lactams against carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii. Antibiotics (Basel). (2022) 11:225. doi: 10.3390/antibiotics11020225,

PubMed Abstract | Crossref Full Text | Google Scholar

47. Bohn, MC, Oltmanns, H, Harting, H, and Meißner, J. N-acetyl cysteine as an additive to bone cement against pathogens involved in periprosthetic joint infections. Front Bioeng Biotechnol. (2025) 13:1595821. doi: 10.3389/fbioe.2025.1595821,

PubMed Abstract | Crossref Full Text | Google Scholar

48. Grimus, V, Coraça-Huber, DC, Steixner, SJM, and Nagl, M. Activity of N-Chlorotaurine against long-term biofilms of Bacteria and yeasts. Antibiotics. (2021) 10:891. doi: 10.3390/antibiotics10080891,

PubMed Abstract | Crossref Full Text | Google Scholar

49. Coraça-Huber, DC, Ammann, CG, Fille, M, Hausdorfer, J, Nogler, M, and Nagl, M. Bactericidal activity of N-chlorotaurine against biofilm-forming bacteria grown on metal disks. Antimicrob Agents Chemother. (2014) 58:2235–9. doi: 10.1128/aac.02700-13,

PubMed Abstract | Crossref Full Text | Google Scholar

50. Steins, A, Carroll, C, Choong, FJ, George, AJ, He, JS, Parsons, KM, et al. Cell death and barrier disruption by clinically used iodine concentrations. Life Sci Alliance. (2023) 6:e202201875. doi: 10.26508/lsa.202201875,

PubMed Abstract | Crossref Full Text | Google Scholar

51. Chen, T-W, Tsai, R-K, Zou, C-E, Huang, C-T, Ali, M, Hsu, T-C, et al. Far-ultraviolet C disinfection reduces oxidative damage to the cornea compared to povidone-iodine disinfection. Antioxidants. (2024) 13:1344. doi: 10.3390/antiox13111344,

PubMed Abstract | Crossref Full Text | Google Scholar

52. Chou, S-F, Lin, C-H, and Chang, S-W. Povidone–iodine application induces corneal cell death through fixation. Br J Ophthalmol. (2011) 95:277. doi: 10.1136/bjo.2010.189407,

PubMed Abstract | Crossref Full Text | Google Scholar

53. Melkus, E, Witte, T, Walter, I, Heuwieser, W, and Aurich, C. Investigations on the endometrial response to intrauterine administration of N-acetylcysteine in oestrous mares. Reprod Domest Anim. (2013) 48:591–7. doi: 10.1111/rda.12131,

PubMed Abstract | Crossref Full Text | Google Scholar

54. He, T, Zhou, H, Li, C, Chen, Y, Chen, X, Li, C, et al. Methylglyoxal suppresses human colon cancer cell lines and tumor growth in a mouse model by impairing glycolytic metabolism of cancer cells associated with down-regulation of C-Myc expression. Cancer Biol Ther. (2016) 17:955–65. doi: 10.1080/15384047.2016.1210736,

PubMed Abstract | Crossref Full Text | Google Scholar

55. Antognelli, C, Mezzasoma, L, Fettucciari, K, and Talesa, VN. A novel mechanism of methylglyoxal cytotoxicity in prostate Cancer cells. Int J Biochem Cell Biol. (2013) 45:836–44. doi: 10.1016/j.biocel.2013.01.003,

PubMed Abstract | Crossref Full Text | Google Scholar

56. Zizkova, P, Viskupicova, J, Heger, V, Rackova, L, Majekova, M, and Horakova, L. Dysfunction of Serca pumps as novel mechanism of methylglyoxal cytotoxicity. Cell Calcium. (2018) 74:112–22. doi: 10.1016/j.ceca.2018.06.003,

PubMed Abstract | Crossref Full Text | Google Scholar

57. Ghosh, A, Bera, S, Ray, S, Banerjee, T, and Ray, M. Methylglyoxal induces mitochondria-dependent apoptosis in sarcoma. Biochem Mosc. (2011) 76:1164–71. doi: 10.1134/S0006297911100105,

PubMed Abstract | Crossref Full Text | Google Scholar

58. Chan, C-M, Huang, D-Y, Huang, Y-P, Hsu, S-H, Kang, L-Y, Shen, C-M, et al. Methylglyoxal induces cell death through endoplasmic reticulum stress-associated Ros production and mitochondrial dysfunction. J Cell Mol Med. (2016) 20:1749–60. doi: 10.1111/jcmm.12893,

PubMed Abstract | Crossref Full Text | Google Scholar

59. Nigro, C, Leone, A, Raciti, GA, Longo, M, Mirra, P, Formisano, P, et al. Methylglyoxal-glyoxalase 1 balance: the root of vascular damage. Int J Mol Sci. (2017) 18:188. doi: 10.3390/ijms18010188,

PubMed Abstract | Crossref Full Text | Google Scholar

60. Rabbani, N, and Thornalley, PJ. Methylglyoxal, glyoxalase 1 and the Dicarbonyl proteome. Amino Acids. (2012) 42:1133–42. doi: 10.1007/s00726-010-0783-0,

PubMed Abstract | Crossref Full Text | Google Scholar

61. Nagl, M, Nguyen, VA, Gottardi, W, Ulmer, H, and Höpfl, R. Tolerability and efficacy of N-Chlorotaurine in comparison with chloramine T for the treatment of chronic leg ulcers with a purulent coating: a randomized phase ii study. Br J Dermatol. (2003) 149:590–7. doi: 10.1046/j.1365-2133.2003.05432.x,

PubMed Abstract | Crossref Full Text | Google Scholar

62. Wirleitner, B, Neurauter, G, Nagl, M, and Fuchs, D. Down-regulatory effect of N-Chlorotaurine on tryptophan degradation and Neopterin production in human Pbmc. Immunol Lett. (2004) 93:143–9. doi: 10.1016/j.imlet.2004.03.006,

PubMed Abstract | Crossref Full Text | Google Scholar

63. Neher, A, Nagl, M, Appenroth, E, Gstöttner, M, Wischatta, M, Reisigl, F, et al. Acute otitis externa: efficacy and tolerability of N-Chlorotaurine, a novel endogenous antiseptic agent. Laryngoscope. (2004) 114:850–4. doi: 10.1097/00005537-200405000-00011,

PubMed Abstract | Crossref Full Text | Google Scholar

64. Zafarullah, M, Li, WQ, Sylvester, J, and Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cellular Molecular Life Sci CMLS. (2003) 60:6–20. doi: 10.1007/s000180300001,

PubMed Abstract | Crossref Full Text | Google Scholar

65. Simpson, S, Kaislasuo, J, Guller, S, and Pal, L. Thermal stability of cytokines: a review. Cytokine. (2020) 125:154829. doi: 10.1016/j.cyto.2019.154829,

PubMed Abstract | Crossref Full Text | Google Scholar

66. Chu, Y, Xu, Y, Yang, W, Chu, K, Li, S, and Guo, L. N-acetylcysteine protects human periodontal ligament fibroblasts from Pyroptosis and osteogenic differentiation dysfunction through the Sirt1/Nf-Κb/Caspase-1 signaling pathway. Arch Oral Biol. (2023) 148:105642. doi: 10.1016/j.archoralbio.2023.105642,

PubMed Abstract | Crossref Full Text | Google Scholar

67. Borges, AM, Healey, GD, and Sheldon, IM. Explants of intact endometrium to model bovine innate immunity and inflammation ex vivo. Am J Reprod Immunol. (2012) 67:526–39. doi: 10.1111/j.1600-0897.2012.01106.x,

PubMed Abstract | Crossref Full Text | Google Scholar

68. Sun, L, Liao, K, Li, Y, Zhao, L, Liang, S, Guo, D, et al. Synergy between polyvinylpyrrolidone-coated silver nanoparticles and azole antifungal against drug-resistant Candida albicans. J Nanosci Nanotechnol. (2016) 16:2325–35. doi: 10.1166/jnn.2016.10934,

PubMed Abstract | Crossref Full Text | Google Scholar

69. Pijls, BG, Sanders, I, Kuijper, EJ, and Nelissen, R. Synergy between induction heating, antibiotics, and N-acetylcysteine eradicates Staphylococcus Aureus from biofilm. Int J Hyperth. (2020) 37:130–6. doi: 10.1080/02656736.2019.1710269,

PubMed Abstract | Crossref Full Text | Google Scholar

70. Aiyer, A, Visser, SK, Bye, P, Britton, WJ, Whiteley, GS, Glasbey, T, et al. Effect of N-acetylcysteine in combination with antibiotics on the biofilms of three cystic fibrosis pathogens of emerging importance. Antibiotics (Basel). (2021) 10:1176. doi: 10.3390/antibiotics10101176,

PubMed Abstract | Crossref Full Text | Google Scholar

71. Hayes, G, Wright, N, Gardner, SL, Telzrow, CL, Wommack, AJ, and Vigueira, PA. Manuka honey and methylglyoxal increase the sensitivity of Staphylococcus Aureus to linezolid. Lett Appl Microbiol. (2018) 66:491–5. doi: 10.1111/lam.12880,

PubMed Abstract | Crossref Full Text | Google Scholar

Keywords: bovine endometritis, alternative antibacterials, cytotoxicity, Trueperella pyogenes, primary cell culture

Citation: Pas D, Oltmanns H and Meißner J (2026) In vitro characterization of antimicrobial efficacy and cytotoxicity of polyvinylpyrrolidone-iodine, N-acetylcysteine, methylglyoxal, and N-chlorotaurine as alternative antimicrobials in treating bovine clinical endometritis. Front. Vet. Sci. 12:1699857. doi: 10.3389/fvets.2025.1699857

Received: 05 September 2025; Revised: 22 November 2025; Accepted: 12 December 2025;
Published: 16 January 2026.

Edited by:

Ana Amaral, University of Lisbon, Portugal

Reviewed by:

Vishal Suthar, Gujarat Biotechnology University, India
Alaa Hassan Said, South Valley University, Egypt

Copyright © 2026 Pas, Oltmanns and Meißner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Dijana Pas, ZGlqYW5hLm1hcmluYS5wYXNAdGloby1oYW5ub3Zlci5kZQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.